Intravenous cyclophosphamide as an alternative to the oral cyclophosphamide modified Ponticelli regimen for high-risk PLA2R-positive membranous nephropathy

被引：0
作者：
Gabriel Ștefan
Adrian Zugravu
Simona Stancu
机构：
[1] University of Medicine and Pharmacy “Carol Davila”,
[2] “Dr. Carol Davila” Teaching Hospital of Nephrology,undefined
[3] Romanian Renal Registry,undefined
来源：
Journal of Nephrology | 2023年 / 36卷
关键词：
High risk primary PLA2R positive membranous nephropathy; Intravenous cyclophosphamide; Cyclic steroid-oral cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：293 / 295
页数：2
相关论文
共 47 条
[1]  
Stefan G(2021)KDIGO 2021 clinical practice guideline for the management of glomerular diseases Kidney Int 100 S1-S276
[2]  
Stancu S(2022)Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy Ren Fail 44 258-268
[3]  
Zugravu A(2021)Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial J Am Soc Nephrol 360 943-949
[4]  
Popa O(2020)Substitution of oral for intravenous cyclophosphamide in membranous nephropathy Kidney 10 450-454
[5]  
Zubidat D(2017)Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy Clin Kidney J undefined undefined-undefined
[6]  
Petre N(undefined)undefined undefined undefined undefined-undefined
[7]  
Mircescu G(undefined)undefined undefined undefined undefined-undefined
[8]  
Scolari F(undefined)undefined undefined undefined undefined-undefined
[9]  
Delbarba E(undefined)undefined undefined undefined undefined-undefined
[10]  
Santoro D(undefined)undefined undefined undefined undefined-undefined
12345